阿加曲班(Argatroban) - 药物靶点：thrombin_在研适应症：肝素诱导的血小板减少伴血栓形成，血栓形成，肝素诱导血小板减少_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Acova、Arganova、Argatra

+ [28]

靶点

thrombin

作用方式

抑制剂

作用机制

thrombin抑制剂(激活型凝血因子II抑制剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [2]

在研适应症

肝素诱导的血小板减少伴血栓形成血栓形成肝素诱导血小板减少+ [6]

非在研适应症

不稳定型心绞痛

原研机构

Mitsubishi Tanabe Pharma Corp.

在研机构

Mitsubishi Tanabe Pharma GmbH

Alfresa Pharma Corp.Mitsubishi Pharma Corp.

+ [7]

非在研机构

Cipla Ltd.Teva Pharmaceuticals USA, Inc.Sandoz, Inc.

权益机构

Ethypharm SAS

The Medicines Co.

Daiichi Sankyo Co., Ltd.

+ [3]

最高研发阶段批准上市

首次获批日期

日本 (1996-04-16),

抗凝血酶III缺乏症脑静脉血栓形成

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H38N6O6S

InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N

CAS号141396-28-3

关联

37

项与阿加曲班相关的临床试验

NCT06442267

/ Recruiting临床4期IIT

A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support

A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an investigator-initiated, prospective, parallel group, open-label, active comparator controlled, single center, phase IV study to evaluate the non-inferiority of enoxaparin or argatroban for anticoagulation during ECMO therapy in comparison to the current standard, unfractionated heparin, as measured by the incidence of thromboembolic events during the duration of ECMO therapy

开始日期2024-07-30

申办/合作机构

Medical University of Vienna

NCT05226442

/ Completed临床2/3期IIT

A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)

This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.

开始日期2021-12-01

申办/合作机构

Medical University of Vienna

EUCTR2021-001456-34-AT

/ Unknown status临床2期IIT

A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)

开始日期2021-07-08

申办/合作机构

Medical University of Vienna

100 项与阿加曲班相关的临床结果

登录后查看更多信息

100 项与阿加曲班相关的转化医学

登录后查看更多信息

100 项与阿加曲班相关的专利（医药）

登录后查看更多信息

1,592

项与阿加曲班相关的文献（医药）

2025-05-01·STROKE

Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial

Article

作者: Khatri, Pooja ; Barreto, Andrew D. ; Grotta, James C. ; Wilson, Alastair ; Roy, Akash ; Derdeyn, Colin P. ; Wintermark, Max ; Adeoye, Opeolu M. ; Shawkat, Adham ; Rines, Ian ; Pizzella, Stephanie ; Broderick, Joseph P.

BACKGROUND::

The modified Rankin Scale (mRS) is a key measure of functional outcomes in stroke trials. To minimize variability, structured tools like the Rankin Focused Assessment and central adjudication are recommended. This study compares local versus centrally adjudicated mRS scores in the MOST trial (Multi-Arm Optimization of Stroke Thrombolysis).

METHODS::

MOST was a phase 3, single-blind, randomized trial evaluating argatroban, eptifibatide, or placebo in addition to intravenous thrombolysis. The primary outcome, 90-day mRS score, was gathered through in-person video recordings by blinded local personnel. Recordings were sent to central adjudicators for final scoring. As in-person visits became limited due to SARS-CoV-2, remote interviews were allowed. We hypothesized that local mRS scores would be moderately associated with central scores. Fleiss-Cohen quadratic weighted κ statistics were used to determine the strength of agreement.

RESULTS::

Out of 514 participants, 378 had recorded visits available (121 in-person video, 157 remote video, 100 remote audio). Local assessors were blinded 96.8% of the time and 85.4% of visits used the Rankin Focused Assessment. Overall agreement between local and central mRS scores was excellent (weighted κ, 0.87 [95% CI, 0.83–0.90]). A nonsignificant decrease in strength of agreement was noted for those with a nonzero baseline mRS (mRS score=0, 0.87 [95% CI, 0.84–0.91] versus mRS score >0, 0.80 [95% CI, 0.68–0.91]). Trial conclusions were unchanged when utilizing the local mRS versus central adjudication.

CONCLUSIONS::

Local mRS scores demonstrated strong agreement with central scores across all assessment modes. With blinded end point assessments, central mRS adjudication in acute stroke trials may not be necessary.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03735979.

2025-04-17·STROKE

Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial.

Article

作者: Gong, Liang ; Sun, Rong ; He, Lanying ; Xu, Xuejun ; Zhao, Hongjian ; Yang, Juan ; Liu, Yinglin ; Li, Yuanyuan ; Wang, Jian ; Liu, Xindong ; Xu, Ronghua ; Zhang, Bei ; Wang, Huazedan ; Ding, Xin ; Xu, Jinghan

BACKGROUND:

Branch atherosclerosis disease (BAD) is prone to early neurological deterioration (END). The purpose of this study was to assess the efficacy and safety of argatroban plus dual antiplatelet therapy (DAPT) for preventing END in high-risk branch atherosclerosis disease patients.

METHODS:

This multicenter, open-label, blinded end point, randomized controlled trial including branch atherosclerosis disease patients with mild stroke (National Institutes of Health Stroke Scale score ≤5) was conducted at 4 centers in China from May 18, 2021 to February 8, 2023. Within 48 hours after symptom onset, patients were randomly assigned to receive argatroban plus DAPT or DAPT alone in a 1:1 ratio. The primary end points were the incidence of END (National Institutes of Health Stroke Scale score increase ≥2) within 7 days and excellent functional outcome (modified Rankin Scale score of 0 to 1) at 90 days.

RESULTS:

A total of 111 patients were randomized, with 11 excluded for specific reasons, resulting in 100 patients included in the modified intention-to-treat population. Among the 100 patients, 49 received argatroban plus DAPT and 51 received DAPT alone, 63 (63.0%) were men, and the median age was 64 (range, 55-74) years. END occurred in 20.4% (10/49) of the argatroban plus DAPT group and 47.1% (24/51) of the DAPT group (risk difference, 26.7% [95% CI, 14.1-39.2]; risk ratio, 2.31 [95% CI, 1.49-3.58]; P=0.006). At the 90-day follow-up, 87.8% (43/49) in the argatroban plus DAPT group and 68.6% (35/51) in the DAPT group achieved an excellent functional outcome (risk difference, -19.1% [95% CI, -30.3 to -8.0]; risk ratio, 0.78 [95% CI, 0.67-0.91]; P=0.025). There was 1 minor hemorrhage in each group.

CONCLUSIONS:

Argatroban plus DAPT is a safe and effective strategy to reduce END occurrence and improve 90-day functional outcome in high-risk branch atherosclerosis disease patients.

REGISTRATION:

URL: https://www.chictr.org.cn; Unique Identifier: ChiCTR21000 46487.

2025-04-03·The International journal of neuroscience

Efficacy of antiplatelet drugs combined with Argatroban in treating acute ischemic stroke and its impact on patients’ coagulation function and neurological function: a preliminary trial

Article

作者: Sun, Meng ; Li, Guoyi ; Zhu, Qiaoyan ; Du, Yingge ; Shi, Zhizhen ; Cheng, Jiwei

This retrospective study analyzed the efficacy of combined antiplatelet therapy with Argatroban in treating acute ischemic stroke (AIS) and its impact on patients' coagulation and neurological functions. Clinical data of 113 AIS patients admitted between January 2021 and January 2023 were retrospectively analyzed. Patients were divided into control (n = 56) and observation (n = 57) groups based on treatment interventions. The control group patients were treated with antiplatelet drugs, while the observation group patients received combination therapy with apatinib on the basis of the control group treatment. Compared to the control group, the observation group demonstrated higher clinical efficacy, improved coagulation parameters, reduced stroke severity (measured by NIHSS), enhanced daily living abilities (BI scores), and lowered inflammatory and neural injury markers post-treatment. Adverse reaction incidence was similar between groups. Combining Argatroban with antiplatelet drugs in AIS management showed superior efficacy without increasing adverse effects, suggesting its potential for clinical application.

142

项与阿加曲班相关的新闻（医药）

2025-05-12

·医脉通

吃感冒药后全身多处紫黑色瘀斑？！患者究竟得了什么病？

医脉通-临床病例平台患者间断发热 25 天，皮肤痛性瘀斑 7 天就诊。25 天前无诱因间断发热，当地抗感染治疗。7 天前服“感冒药”后腹痛，多部位皮肤出现紫黑色瘀斑伴烧灼样痛，范围扩大，累及多处皮肤，呈对称性分布，出现水疱、破溃。既往诊断门静脉血栓等 3 年，阿加曲班抗凝后自行停药。猜一猜，这个患者情况是什么疾病导致的？点击文末阅读原文查看完整病例，一起讨论想法！5月13日上午10：00，原帖揭晓答案！验证你的猜想！-李猛教授-解放军总医院血液病医学部血液科副主任医师、副教授主持或参与多项军队课题、国家自然基金课题国内外发表论文30余篇中国老年医学会感染管理控制分会委员全国卫生产业企业管理协会手术室及相关受控空间分会理事《中华医院感染学杂志》编委会编委END医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

AHA会议

2025-05-06

·梅斯医学

每治疗4人避免1例恶化！Stroke：新型抗栓方案让脑梗恶化风险直降57%

对于一种特殊类型的脑梗——分支动脉粥样硬化病（BAD）患者来说，病情突然加重的噩梦或将终结！中国四大医疗中心联合开展的最新临床研究显示，在传统双抗治疗（DAPT）基础上加用阿加曲班，可将早期神经功能恶化（END）风险从47.1%骤降至20.4%，降幅高达57%。更令人振奋的是，这种三联抗栓方案还能显著改善患者三个月后的康复效果，让近九成患者恢复近乎正常的生活能力，且不增加严重出血风险。这项针对高危BAD患者的前瞻性研究，在2021至2023年间纳入了100名轻型卒中患者。这些患者虽然入院时症状较轻（NIHSS评分≤5分），但都属于极易发生病情恶化的高危人群。研究采用创新的"开放标签、终点设盲"设计，将患者随机分为两组：一组接受标准双抗治疗（阿司匹林+氯吡格雷），另一组在此基础上加用静脉阿加曲班。结果令人惊喜：三联方案组仅20.4%患者出现病情恶化，而传统治疗组这一比例高达47.1%。这意味着每治疗4名患者，就能多避免1例病情加重。病情稳定只是第一步，功能恢复才是硬道理。90天随访数据显示，三联治疗组87.8%的患者恢复良好（mRS评分0-1分），而传统治疗组仅为68.6%。换算成绝对风险差，相当于每5名接受强化治疗的患者，就有1人额外获得近乎完全康复的机会。特别值得一提的是，两组仅各出现1例轻微出血事件，证明这种强化抗栓方案安全性可控。对于平均年龄64岁的卒中患者群体而言，这样的疗效与安全性平衡实属难得。为什么阿加曲班能有如此神奇的效果？专家解释，BAD患者的血管病变特殊，容易在分支开口处形成白色血栓，而传统抗血小板药物对这类血栓效果有限。阿加曲班作为直接凝血酶抑制剂，能更精准地阻断血栓形成的关键环节。研究负责人指出："这就像防汛，双抗是加固堤坝，而加用阿加曲班相当于增加了泄洪通道，双管齐下才能有效防范'决堤'风险。"这种靶向治疗策略的突破，为个体化抗栓治疗提供了新思路。目前，该治疗方案已在国内多家医院推广应用。医生特别提醒，虽然疗效显著，但强化抗栓必须严格掌握适应症，尤其要排除出血高风险患者。对于确诊BAD的轻型卒中患者，尤其是影像学显示存在血流动力学障碍者，可考虑在医生指导下采用这种三联方案。随着更多证据积累，这种"双抗打底、精准加药"的治疗模式，或将成为特殊类型脑梗的一线选择，让更多患者避免病情恶化之苦，重获高质量生活。参考资料：[1]Xu J, et al. Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial. Stroke. 2025 Apr17. doi: 10.1161/STROKEAHA.124.048872.撰文 | 梅斯医学编辑 | 木白● 燃气灶致癌？最新研究：释放一级致癌物，增加患癌风险；仅烹饪1小时，释放的NO2远超阈值，增加死亡率和哮喘发生率！这种方法可缓解● 非必要不做CT！最新研究：CT辐射或引发10万例新发癌症；每多做一次CT，血液肿瘤风险升43％；超过该剂量，脑癌风险飙升400％● 微创手术花了393元，患者嫌贵，吐槽被医院忽悠了！医生回应：想要得到救治，又不想花钱，检查多一点就是忽悠你？烫个头也得几百呢版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床研究临床结果

2025-04-17

·米内网

【火热】山东药企抢攻百亿市场，首款产品剑指20亿品种

精彩内容近日，山东新时代药业获批了罗沙司他胶囊和曲氟尿苷替匹嘧啶片，今年以来已累计获批了8个新产品。罗沙司他是抗贫血制剂重磅品种，2023年在中国三大终端六大市场的销售额超过20亿元，该产品是山东新时代药业首款抗贫血制剂。图1：山东新时代药业最新获批的产品来源：国家药监局官网罗沙司他胶囊适用于慢性肾脏病(CKD)引起的贫血，包括透析及非透析患者。米内网数据显示，山东新时代药业是该产品第17家获批企业。图2：罗沙司他胶囊的销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），罗沙司他胶囊的销售额在2021年突破13亿元，2023年涨至20亿元以上，2024上半年再有12.86%的增长，是抗贫血制剂（化+生）市场内服TOP1产品。早前，山东新时代药业在血液和造血系统药物市场仅有6个抗血栓形成药获批，包括了阿加曲班注射液、阿哌沙班片、甲苯磺酸艾多沙班片、利伐沙班片、依诺肝素钠注射液和注射用盐酸替罗非班。本次获批的罗沙司他胶囊是公司首款抗贫血制剂，2023年在中国三大终端六大市场抗贫血制剂（化+生）的销售规模已涨至145亿元。曲氟尿苷替匹嘧啶片是一款抗肿瘤药，2023年在中国三大终端六大市场的销售额在1.6亿元以上，山东新时代药业是该产品第4家获批的国内药企。表1：山东新时代药业今年以来获批的新产品来源：米内网中国申报进度（MED）数据库今年以来，山东新时代药业已累计获批了8个高端仿制药，其中琥珀酸普芦卡必利片是公司首款治疗便秘的化药，罗沙司他胶囊是公司首款抗贫血制剂，公司在2025年已开拓了两个新市场。资料来源：国家药监局官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至4月16日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

100 项与阿加曲班相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00181	阿加曲班	B01AE03	DB00278

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肝素诱导的血小板减少伴血栓形成	日本	Alfresa Pharma Corp.	2008-07-16
血栓形成	日本	Mitsubishi Tanabe Pharma Corp.	2005-07-01
肝素诱导血小板减少	丹麦	Mitsubishi Tanabe Pharma GmbH	2005-03-01
肝素诱导血小板减少	意大利	Mitsubishi Tanabe Pharma GmbH	2005-03-01
肝素诱导血小板减少	挪威	Mitsubishi Tanabe Pharma GmbH	2005-03-01
肝素诱导血小板减少	西班牙	Mitsubishi Tanabe Pharma GmbH	2005-03-01
肝素诱导血小板减少	瑞典	Mitsubishi Tanabe Pharma GmbH	2005-03-01
肝素诱导血小板减少	英国	Mitsubishi Tanabe Pharma GmbH	2005-03-01
动脉硬化闭塞症	中国	Mitsubishi Pharma Corp.	2002-08-02
缺血性脑梗死	中国	Mitsubishi Pharma Corp.	2002-08-02
血栓闭塞性血管炎	中国	Mitsubishi Pharma Corp.	2002-08-02
血小板减少症	美国	Sandoz, Inc.	2000-06-30
抗凝血酶III缺乏症	日本	Alfresa Pharma Corp.	1996-04-16
脑静脉血栓形成	日本	Alfresa Pharma Corp.	1996-04-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不稳定型心绞痛	临床2期	比利时	Mitsubishi Tanabe Pharma Corp.	2005-08-01
不稳定型心绞痛	临床2期	德国	Mitsubishi Tanabe Pharma Corp.	2005-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03735979 (phase 3 \| MOST, CTgov)	临床3期	急性缺血性卒中	514	Argatroban (Argatroban)	艱觸簾淵選遞顧淵窪築(夢構獵鑰鹽積醖選艱鹽) = 選簾製襯鑰鬱衊構鹹襯鹹餘醖鑰選鑰繭築窪鑰 (醖壓繭廠鏇淵網構蓋壓, 3.7) 更多	-	2024-11-19
				Eptifibatide (Eptifibatide)	艱觸簾淵選遞顧淵窪築(夢構獵鑰鹽積醖選艱鹽) = 夢選積膚範艱繭糧淵範鹹餘醖鑰選鑰繭築窪鑰 (醖壓繭廠鏇淵網構蓋壓, 3.2) 更多
NCT03735979 (MOST, Literature \| Pubmed \| N Engl J Med) 人工标引	临床3期	缺血性卒中辅助	514	Argatroban	餘壓衊網壓夢鬱鹹衊觸(壓壓艱淵艱醖壓壓餘選) = 艱構築繭網艱簾蓋餘獵築壓觸繭鏇衊廠範顧蓋 (築築艱膚製鏇鬱蓋艱鹽 ) 更多	不佳	2024-09-04
				Eptifibatide	餘壓衊網壓夢鬱鹹衊觸(壓壓艱淵艱醖壓壓餘選) = 襯選觸獵艱構醖願鏇積築壓觸繭鏇衊廠範顧蓋 (築築艱膚製鏇鬱蓋艱鹽 ) 更多
NCT05740371 (SAICoDis, CTgov)	临床4期	不稳定型心绞痛	50	Argatroban (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population))	選齋顧鏇願繭網鑰齋鏇(選積壓鏇願衊鹹築淵壓) = 糧廠壓簾選製構觸壓構夢構範築壓夢鑰壓壓淵 (襯糧齋壓網鏇淵廠壓選, 46.37)	-	2024-03-18
				Argatroban (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male))	鑰製淵糧餘鹽構顧製蓋(膚遞簾廠壓艱獵網積艱) = 憲網選遞淵衊繭齋鬱選構膚構獵簾顧鹹襯窪膚 (蓋餘築艱網艱齋獵鹽膚, 46.4072)
NCT04406389 (IMPACT, CTgov)	临床4期	新型冠状病毒感染	14	Unfractionated heparin+Fondapariniux+Enoxaparin sodium (Intermediate Dose Prophylaxis)	鹽遞築簾淵衊壓鹹願窪 = 蓋築廠壓選願築糧製觸願鬱膚繭鹽窪鬱廠繭簾 (艱遞憲衊廠構獵範齋襯, 齋繭鏇齋膚製夢構鏇繭 ~ 窪積齋襯齋憲鹽艱構顧) 更多	-	2023-09-21
				Unfractionated heparin+Fondapariniux+Argatroban+Enoxaparin sodium (Therapeutic Dose Anticoagulation)	鹽遞築簾淵衊壓鹹願窪 = 醖築窪鹽網繭網鹽築簾願鬱膚繭鹽窪鬱廠繭簾 (艱遞憲衊廠構獵範齋襯, 構蓋鑰網遞鬱範糧鬱鬱 ~ 製糧餘構淵觸鏇淵鬱鬱) 更多
NCT03740958 (ARIAIS, Pubmed \| JAMA)	临床4期	急性缺血性卒中	808	Argatroban plus Alteplase	廠糧網繭淵窪製構網簾(選衊顧廠簾鬱夢簾夢鹽) = 構窪糧夢壓淵網艱壓觸鏇網築糧齋壓鬱糧網鹽 (繭廠繭鹽夢繭鑰衊鏇襯 ) 更多	不佳	2023-02-09
				Alteplase alone	廠糧網繭淵窪製構網簾(選衊顧廠簾鬱夢簾夢鹽) = 襯選選夢選壓窪積齋夢鏇網築糧齋壓鬱糧網鹽 (繭廠繭鹽夢繭鑰衊鏇襯 ) 更多
ISTH2022	N/A	肝素诱导血小板减少 \| 肝素诱导的血小板减少伴血栓形成	-	Argatroban	範壓淵製鬱觸積衊鬱鏇(顧鏇構遞繭鏇憲鬱膚憲) = 糧襯遞壓蓋淵衊淵鏇構願艱壓醖顧觸鬱製構積 (艱遞願壓簾糧網醖齋鑰 )	-	2022-07-09
				Patients with Vaccine Induced Thrombocytopenia with Thrombosis	範壓淵製鬱觸積衊鬱鏇(顧鏇構遞繭鏇憲鬱膚憲) = 鹹鑰鏇網網鹹鑰壓鹽鬱願艱壓醖顧觸鬱製構積 (艱遞願壓簾糧網醖齋鑰 )
NCT01734252 (not provided, Pubmed \| J Clin Med)	临床2期	-	42	Argatroban	獵鑰壓壓範顧積醖醖艱(構醖網獵餘糧鹹齋遞網) = 願夢衊壓艱醖遞鏇繭壓願鑰膚簾膚願鬱鑰簾網 (鬱壓網鹽壓壓鏇顧襯顧 ) 更多	积极	2020-03-31
				Increased dose of unfractionated heparin (UFH)	獵鑰壓壓範顧積醖醖艱(構醖網獵餘糧鹹齋遞網) = 醖壓範繭夢壓壓醖構鏇願鑰膚簾膚願鬱鑰簾網 (鬱壓網鹽壓壓鏇顧襯顧 ) 更多
ISTH2019	N/A	肝素诱导血小板减少 soluble fibrin monomers (FM)	11	argatroban	廠範觸壓積築顧醖膚鹽(壓壓積築願糧構鬱鑰餘) = 遞淵鏇廠顧鏇觸窪淵窪鹽範製繭鏇鹽鑰襯顧醖 (醖顧觸齋醖鑰鹽鏇觸淵 )	-	2019-06-10
ISTH2019	N/A	肝素诱导血小板减少	605	argatroban	憲鹽窪廠憲衊網築構艱(觸憲衊鬱襯醖衊鬱範齋) = 觸餘廠鹽選構醖衊鬱襯繭範膚壓艱觸網夢鏇製 (鏇淵鏇網觸膚餘願鏇範 ) 更多	-	2019-06-10
EHA2019	N/A	肝素诱导血小板减少	-	Argatroban	蓋願艱壓製壓糧鬱鹽鬱(選繭淵製繭積蓋憲齋鹹) = 簾鹽選餘窪膚窪繭鬱網廠壓糧齋選蓋夢築鏇鏇 (醖襯選鏇選構繭鬱網獵 )	-	2019-05-16